AI and patent protection

2021 ◽  
pp. 75-148
Author(s):  
Ana Ramalho
Keyword(s):  
2020 ◽  
pp. 18-21
Author(s):  
E. Blynskaya ◽  
S. Tishkov ◽  
V. Bueva ◽  
K. Alekseev ◽  
V. Alekseev ◽  
...  

Medicated chewing gum is a convenient dosage form that allows to expand the range of medicines, ensure adherence of patients to the treatment and extend patent protection for well-known names of medicines. This article describes the technological properties of the Health in Gum® chewing gum base, which provides medicinal chewing gums with minimal addition of excipients by direct compression.


2014 ◽  
Vol 4 (1) ◽  
Author(s):  
Rupesh Rastogi ◽  
Virendra Kumar

The first legislation in India relating to patents was the Act VI of 1856. The Indian Patents and Design Act, 1911 (Act II of 1911) replaced all the previous Acts. The Act brought patent administration under the management of Controller of Patents for the first time. After Independence, it was felt that the Indian Patents & Designs Act, 1911 was not fulfilling its objective. Various comities were constituted to recommend, framing a patent law which can fulfill the requirement of Indian Industry and people. The Indian Patent Act of 1970 was enacted to achieve the above objectives. The major provisions of the act, provided for process, not the product patents in food, medicines, chemicals with a term of 14 years and 5-7 for chemicals and drugs. The Act enabled Indian citizens to access cheapest medicines in the world and paved a way for exponential growth of Indian Pharmaceutical Industry. TRIPS agreement, which is one of the important results of the Uruguay Round, mandated strong patent protection, especially for pharmaceutical products, thereby allowing the patenting of NCEs, compounds and processes. India is thereby required to meet the minimum standards under the TRIPS Agreement in relation to patents and the pharmaceutical industry. India’s patent legislation must now include provisions for availability of patents for both pharmaceutical products and processes inventions. The present paper examines the impact of change in Indian Patent law on Pharmaceutical Industry.


2013 ◽  
Vol 1 (3) ◽  
pp. 1-6
Author(s):  
Pankaj Kashyap ◽  
Eshant Duggal ◽  
Parveen Budhwar ◽  
Jitendra Kumar Badjatya

Generic medicines are those whose patent protection has expired, and which may be produced by manufacturers otherthan the innovator company. Use of generic medicines has been increasing in recent years, primarily as a cost savingmeasure in healthcare provision. Generic medicines are typically 20 to 90% cheaper than originator equivalents. Theobjective is to provide a high-level description of what generic medicines are and how they differ, at a regulatory andlegislative level, from originator medicines. It describes the current and historical regulation of medicines in theworld’s two main pharmaceutical markets, in addition to the similarities, as well as the differences, between genericsand their originator equivalents including the reasons for the cost differences seen between originator and genericmedicines. This article refers to the general generic drug approval process in India, USA, and Japan. They havedifferent regulation and approval process. 


Author(s):  
Noam Shemtov

This chapter examines the scope of protection to which graphical user interfaces may be eligible under various intellectual property rights: namely, trade marks, unfair-competition laws, design rights, copyright, and patents. It first considers the extent of copyright protection over a software product’s ‘look-and-feel’ elements, with particular emphasis on graphical user interfaces protection under US and EU laws. It then discusses trade-mark, trade-dress, and unfair-competition protection for graphical user interfaces, along with intellectual property rights protection for design patents and registered designs. Finally, it describes the patent protection for graphical user interfaces in the United States and at the European Patent Office.


2019 ◽  
Vol 33 (2) ◽  
pp. 395-411 ◽  
Author(s):  
Angus C. Chu ◽  
Zonglai Kou ◽  
Xilin Wang

Abstract This study provides a growth-theoretic analysis of the effects of intellectual property rights on the take-off of an economy from an era of stagnation to a state of sustained economic growth. We incorporate patent protection into a Schumpeterian growth model in which take-off occurs when the population size crosses an endogenous threshold. We find that strengthening patent protection has contrasting effects on economic growth at different stages of development. Specifically, it leads to an earlier take-off but also reduces economic growth in the long run.


NANO ◽  
2006 ◽  
Vol 01 (02) ◽  
pp. 101-113 ◽  
Author(s):  
LINDA L. LEE ◽  
CASEY K. CHAN ◽  
MICHELLE NGIAM ◽  
SEERAM RAMAKRISHNA

Touted as the technological revolution of the 21st century, nanotechnology has already been the topic of numerous publications, patents and news stories. While the commercial applications of nanotechnology are still relatively few, they are beginning to attract the attention of the commercial sector. For successful commercialization of this emerging technology, patent protection is imperative. Patents are publicly available documents forming a rich repository of current knowledge. By a systematic method of collecting, organizing and analyzing these publicly available documents, valuable information can be distilled about the activities and opportunities within this emerging field. As this field is rapidly progressing, this paper provides a summary of current patent issues in nanotechnology, an overview of nanotechnology patent analyses and the latest update of the current landscape of nanotechnology patents.


Sign in / Sign up

Export Citation Format

Share Document